This program will be broadcast live from the 2024 COA Community Oncology Conference in Orlando, Florida.
Program Description
Clinical practice guidelines continue to evolve to incorporate chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies (BsAbs) as treatment options for patients with relapsed or refractory multiple myeloma (MM). Despite the utility of CAR T-cell therapy and BsAbs, the complex logistics, access and reimbursement issues, and infrastructure required for the delivery of CAR T-cell therapies and BsAbs have hindered their integration into MM treatment paradigms. Oncology pharmacists practicing within community settings can help prioritize access to these therapies and ensure patient safety through the management of unique treatment-related toxicities. This session will examine clinical practice guideline updates for the sequencing and combination strategies involving CAR T-cell therapies and BsAbs in the treatment algorithm of MM. Within the community setting, oncology pharmacists can have essential roles in navigating the complexities of these therapies for MM. At the completion of this activity, they will be equipped to assist in optimizing patient outcomes through comprehensive patient assessment, proactive management of adverse effects, and ongoing communication with the multidisciplinary team to ensure coordinated care.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: April 4, 2024
Expiration date: June 4, 2024
Time to complete activity: 0.75 hour
Learner level: Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Investigate clinical practice guidelines and advancements in clinical evidence for the use of bispecific antibodies (BsAbs) and CAR T-cell therapies for patients with multiple myeloma (MM)
- Identify obstacles disrupting the integration of novel BsAbs and CAR T-cell therapies into MM treatment regimens in community practice settings
- Explore strategies to improve the implementation of novel therapies for the treatment of MM into community oncology practices
Joseph Kalis, PharmD, BCOP
Ambulatory Oncology Pharmacist
UCHealth Hematology/Oncology
Colorado Springs, Colorado
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hour (0.075 CEU) under the ACPE universal activity number 0290-0000-24-027-L01-P. The activity is available for CE credit through June 4, 2024.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Joseph Kalis, PharmD, BCOP, has no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Amy H. Seung, PharmD, BCOP, FHOPA, CHCP; Rose Buszka, PharmD, BCPS, CHCP; Crissy Wilson; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of se Information:
www.pharmacytimes.org/terms